<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326117</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00027389</org_study_id>
    <nct_id>NCT01326117</nct_id>
  </id_info>
  <brief_title>Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis</brief_title>
  <official_title>Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mark Feinglos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that in adult patients with diabetic gastroparesis with Type 1
      diabetes (HbA1c ≤ 10.5%), daily tadalafil use will significantly improve gastric emptying
      compared to baseline as measured by gastric emptying time.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of patients who meet inclusion criteria; there was one screen failure
  </why_stopped>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in Gastric Emptying Study residual tracer amount</measure>
    <time_frame>7 days with intervention</time_frame>
    <description>change in gastric emptying compared to baseline as measured by gastric emptying time.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Diabetic Gastroparesis</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>7 days of Cialis for Daily Use (5mg)</description>
    <arm_group_label>tadalafil</arm_group_label>
    <other_name>Cialis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes diagnosis

          -  Age 18 - 65 years (inclusive)

          -  Hemoglobin A1c ≤ 10.5% within the last 4 months

          -  Diagnosis of gastroparesis, or symptoms consistent with gastroparesis (early satiety,
             chronic intermittent nausea or vomiting with food intake)

          -  Patient has gastroparesis confirmed on screening study

          -  A female patient is eligible to participate if she is of: Non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or
             postmenopausal defined as 12 months of spontaneous amenorrhea, or child-bearing
             potential with negative serum hCG prior to each gastric emptying study.

        Exclusion Criteria:

          -  Active nitrate use (e.g. Cialis, Viagra, Levitra, nitroglycerin, Isordil, Imdur, amyl
             nitrate/poppers)

          -  Fasting fingerstick glucose &gt; 250 mg/dL

          -  History of abdominal surgery including gastric banding procedure

          -  Patient is on chronic parenteral feeding

          -  Patient has a history of eating disorders (anorexia nervosa, binge eating, bulimia)

          -  Regular opiate use

          -  Recent (last 6 weeks) history of poor control of diabetes e.g. hypoglycemia requiring
             medical intervention, diabetic ketoacidosis, admission for control diabetes or
             complications of diabetes

          -  Acute severe gastroenteritis

          -  The patient has participated in another clinical trial in the last 30 days.

          -  Use of medications potentially influencing upper gastrointestinal motility or appetite
             within one week of the study [e.g., prokinetic drugs, macrolide antibiotics
             (erythromycin), GLP-1 mimetics/analog, amylin analog]

          -  History or presence of clinically significant gastro-intestinal, hepatic or renal
             disease or other condition that would in the opinion of the investigator make the
             subject unsuitable for inclusion in this clinical study.

          -  Chronic angina or NYHA class III or IV CHF

          -  Concurrent use of ketoconazole or itraconazole

          -  History of severe vision loss, retinitis pigmentosa, or non-arteritic anterior
             ischemic optic neuropathy (NAION)

          -  History of CVA

          -  Pregnant females as determined by positive serum hCG test

          -  Lactating females

          -  Uncontrolled hypertension (SBP &gt; 160 or DBP &gt; 100)

          -  Hypotension (SBP &lt; 90 or DBP &lt; 60)

          -  Other major medical conditions: priapism, sickle cell anemia, multiple myeloma,
             leukemia, active cancer diagnosis, HIV/AIDS, alcoholism, or bleeding diathesis.

          -  Intolerance to active or inactive ingredients of Cialis, or intolerance to other PDE-5
             inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark N Feinglos, MD, CM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>July 25, 2014</last_update_submitted>
  <last_update_submitted_qc>July 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Mark Feinglos</investigator_full_name>
    <investigator_title>Division Chief, Department of Endocrinology, Diabetes, and Metabolism</investigator_title>
  </responsible_party>
  <keyword>gastroparesis</keyword>
  <keyword>gastric emptying</keyword>
  <keyword>diabetes</keyword>
  <keyword>Stomach Diseases</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Phosphodiesterase Inhibitors</keyword>
  <keyword>Neurologic Manifestations</keyword>
  <keyword>Paralysis</keyword>
  <keyword>Signs and Symptoms</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

